<p>Bicara Therapeutics Inc.（纳斯达克代码：BCAX - 获取免费报告）首席财务官 Ivan Hyep 于 1 月 22 日星期四出售了 1,882 股该股票。股票的平均售价为 18.15 美元，总交易额为 34,158.30 美元。交易后，首席财务官持有 145,355 股公司股票，价值 2,638,193.25 美元。此次交易使其持股减少了 1.28%。该出售在向 SEC 的法律文件中披露，您可以通过此超链接访问。</p>
<p>获取 <strong>Bicara Therapeutics</strong> 的提醒：</p>
<p>Ivan Hyep 最近还进行了以下交易：</p>
<ul>
<li>在 11 月 24 日星期一，Ivan Hyep 出售了 17,795 股 Bicara Therapeutics 股票。股票的平均售价为 18.55 美元，总交易额为 330,097.25 美元。</li>
<li>在 11 月 21 日星期五，Ivan Hyep 出售了 605 股 Bicara Therapeutics 股票。股票的平均售价为 18.15 美元，总交易额为 10,980.75 美元。</li>
</ul>
<h2>Bicara Therapeutics 股价下跌 1.9%</h2>
<p>在周一的交易中，纳斯达克代码：BCAX 的股票下跌了 0.32 美元，跌至 16.42 美元。该公司交易了 567,617 股，相较于其平均交易量 484,589 股。Bicara Therapeutics Inc.的 52 周低点为 7.80 美元，52 周高点为 19.71 美元。该公司的 50 日移动平均价格为 17.45 美元，200 日移动平均价格为 14.72 美元。该股票的市值为 8.9949 亿美元，市盈率为-7.33，贝塔值为-0.79。</p>
<p>Bicara Therapeutics（纳斯达克代码：BCAX - 获取免费报告）最近在 11 月 10 日星期一发布了季度财报。公司报告每股收益（EPS）为-0.67 美元，低于市场共识预期的-0.55 美元，差距为 0.12 美元。整体来看，研究分析师预测 Bicara Therapeutics Inc.在当前年度将发布-2.59 的每股收益。</p>
<h2>分析师设定新的价格目标</h2>
<p>几位研究分析师最近对 BCAX 股票发表了评论。富国银行将 Bicara Therapeutics 的目标价格从 8.00 美元上调至 11.00 美元，并在 11 月 11 日的研究报告中给予该股票 “持平” 评级。Wedbush 在 1 月 13 日的报告中重申了 “跑赢大盘” 评级，并设定了 30.00 美元的价格目标。瑞穗证券在 12 月 18 日的报告中将 Bicara Therapeutics 的股票评级上调至 “持有”。瑞银集团在 1 月 14 日的研究报告中重申了对 Bicara Therapeutics 股票的 “买入” 评级。最后，HC Wainwright 在 1 月 14 日的报告中重申了对 Bicara Therapeutics 股票的 “买入” 评级。六位分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均价格目标为 28.00 美元。</p>
<p><strong>阅读我们关于 Bicara Therapeutics 的最新股票报告</strong></p>
<h2>机构资金流入和流出</h2>
<p>一些机构投资者和对冲基金最近增加或减少了对 BCAX 的持股。Legal &amp; General Group Plc 在第二季度将其在 Bicara Therapeutics 的持股增加了 64.1%。Legal &amp; General Group Plc 目前拥有 3,156 股公司股票，价值 29,000 美元，此前在该期间内又购买了 1,233 股。Ameritas Investment Partners Inc.在第二季度将其在 Bicara Therapeutics 的持股增加了 73.0%。Ameritas Investment Partners Inc.目前拥有 3,493 股公司股票，价值 32,000 美元，此前在上一季度又收购了 1,474 股。Tower Research Capital LLC TRC 在第二季度将其在 Bicara Therapeutics 的持股增加了 419.3%。Tower Research Capital LLC TRC 目前拥有 4,788 股公司股票，价值 44,000 美元，此前在该期间内又收购了 3,866 股。Mirae Asset Global Investments Co. Ltd.在第四季度收购了 Bicara Therapeutics 的新股份，价值约 45,000 美元。最后，Larson Financial Group LLC 在第三季度将其在 Bicara Therapeutics 的持股增加了 1,015.5%。Larson Financial Group LLC 目前拥有 3,949 股公司股票，价值 62,000 美元，此前在上一季度又购买了 3,595 股。</p>
<h2>关于 Bicara Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Bicara Therapeutics 是一家临床阶段的生物制药公司，致力于开发新型基于神经激素的疗法，以治疗精神和神经疾病。公司的研究专注于利用大脑中的内源性信号通路，旨在为现有药物无法充分解决的疾病提供新的治疗选择。Bicara 应用专有的肽工程和鼻用给药平台，以优化中枢神经系统的吸收和治疗效果。</p>
<p>公司的主要候选药物包括 PST-001，一种用于产后抑郁症的鼻用抗加压素 1A 受体拮抗剂，以及 PST-002，一种正在研究用于社交焦虑和自闭症谱系障碍的催产素受体调节剂。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更喜欢的五只股票比 Bicara Therapeutics 更好</li>
<li>您的签名缺失 - 在为时已晚之前采取行动</li>
<li>什么费用可以从资本利得税中扣除？</li>
<li>将这些代码输入您的普通经纪账户</li>
<li>用这 4 个简单步骤 “防止美联储影响” 您的银行账户</li>
<li>在星期一上午 9:30 购买这只股票！</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkNBWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkNBWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元于 Bicara Therapeutics 吗？</h2>
<p>在您考虑 Bicara Therapeutics 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Bicara Therapeutics 并不在名单上。</p>
<p>虽然 Bicara Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

BCAX

<p>Bicara Therapeutics 首席财务官 Ivan Hyep 以每股 18.15 美元的价格出售了 1,882 股，总计 34,158.30 美元，减少了 1.28% 的持股比例。出售后，他持有 145,355 股，价值约 264 万美元。该股票近期出现下跌，交易价格下跌 1.9% 至 16.42 美元。分析师对该股票的评级意见不一，普遍评级为 “适度买入”，平均目标价为 28.00 美元。机构投资者最近也调整了在公司的持股比例</p>

<p>Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CFO Ivan Hyep sold 1,882 shares of the stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $18.15, for a total transaction of $34,158.30. Following the transaction, the chief financial officer owned 145,355 shares of the company's stock, valued at $2,638,193.25. The trade was a 1.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.</p>
<div class="lb-trans"><p>Bicara Therapeutics Inc.（纳斯达克代码：BCAX - 获取免费报告）首席财务官 Ivan Hyep 于 1 月 22 日星期四出售了 1,882 股该股票。股票的平均售价为 18.15 美元，总交易额为 34,158.30 美元。交易后，首席财务官持有 145,355 股公司股票，价值 2,638,193.25 美元。此次交易使其持股减少了 1.28%。该出售在向 SEC 的法律文件中披露，您可以通过此超链接访问。</p>
</div><p>Get <strong>Bicara Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Bicara Therapeutics</strong> 的提醒：</p>
</div><p>Ivan Hyep also recently made the following trade(s):</p>
<div class="lb-trans"><p>Ivan Hyep 最近还进行了以下交易：</p>
</div><ul>
<li>On Monday, November 24th, Ivan Hyep sold 17,795 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.55, for a total transaction of $330,097.25.</li>
<li>On Friday, November 21st, Ivan Hyep sold 605 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.15, for a total transaction of $10,980.75.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 11 月 24 日星期一，Ivan Hyep 出售了 17,795 股 Bicara Therapeutics 股票。股票的平均售价为 18.55 美元，总交易额为 330,097.25 美元。</li>
<li>在 11 月 21 日星期五，Ivan Hyep 出售了 605 股 Bicara Therapeutics 股票。股票的平均售价为 18.15 美元，总交易额为 10,980.75 美元。</li>
</ul>
</div><h2>Bicara Therapeutics Trading Down 1.9%</h2>
<div class="lb-trans"><h2>Bicara Therapeutics 股价下跌 1.9%</h2>
</div><p>Shares of NASDAQ:BCAX traded down $0.32 during trading on Monday, hitting $16.42. 567,617 shares of the company were exchanged, compared to its average volume of 484,589. Bicara Therapeutics Inc. has a fifty-two week low of $7.80 and a fifty-two week high of $19.71. The firm has a fifty day moving average price of $17.45 and a two-hundred day moving average price of $14.72. The stock has a market cap of $899.49 million, a price-to-earnings ratio of -7.33 and a beta of -0.79.</p>
<div class="lb-trans"><p>在周一的交易中，纳斯达克代码：BCAX 的股票下跌了 0.32 美元，跌至 16.42 美元。该公司交易了 567,617 股，相较于其平均交易量 484,589 股。Bicara Therapeutics Inc.的 52 周低点为 7.80 美元，52 周高点为 19.71 美元。该公司的 50 日移动平均价格为 17.45 美元，200 日移动平均价格为 14.72 美元。该股票的市值为 8.9949 亿美元，市盈率为-7.33，贝塔值为-0.79。</p>
</div><p>Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.12). As a group, research analysts predict that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.</p>
<div class="lb-trans"><p>Bicara Therapeutics（纳斯达克代码：BCAX - 获取免费报告）最近在 11 月 10 日星期一发布了季度财报。公司报告每股收益（EPS）为-0.67 美元，低于市场共识预期的-0.55 美元，差距为 0.12 美元。整体来看，研究分析师预测 Bicara Therapeutics Inc.在当前年度将发布-2.59 的每股收益。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>Several research analysts have recently commented on BCAX shares. Wells Fargo &amp; Company lifted their target price on Bicara Therapeutics from $8.00 to $11.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Tuesday, November 11th. Wedbush reaffirmed an &#34;outperform&#34; rating and set a $30.00 price target on shares of Bicara Therapeutics in a report on Tuesday, January 13th. Mizuho upgraded shares of Bicara Therapeutics to a &#34;hold&#34; rating in a report on Thursday, December 18th. UBS Group reissued a &#34;buy&#34; rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Finally, HC Wainwright reaffirmed a &#34;buy&#34; rating on shares of Bicara Therapeutics in a report on Wednesday, January 14th. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $28.00.</p>
<div class="lb-trans"><p>几位研究分析师最近对 BCAX 股票发表了评论。富国银行将 Bicara Therapeutics 的目标价格从 8.00 美元上调至 11.00 美元，并在 11 月 11 日的研究报告中给予该股票 “持平” 评级。Wedbush 在 1 月 13 日的报告中重申了 “跑赢大盘” 评级，并设定了 30.00 美元的价格目标。瑞穗证券在 12 月 18 日的报告中将 Bicara Therapeutics 的股票评级上调至 “持有”。瑞银集团在 1 月 14 日的研究报告中重申了对 Bicara Therapeutics 股票的 “买入” 评级。最后，HC Wainwright 在 1 月 14 日的报告中重申了对 Bicara Therapeutics 股票的 “买入” 评级。六位分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均价格目标为 28.00 美元。</p>
</div><p><strong>Read Our Latest Stock Report on Bicara Therapeutics</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Bicara Therapeutics 的最新股票报告</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of institutional investors and hedge funds have recently added to or reduced their stakes in BCAX. Legal &amp; General Group Plc increased its position in Bicara Therapeutics by 64.1% during the 2nd quarter. Legal &amp; General Group Plc now owns 3,156 shares of the company's stock worth $29,000 after buying an additional 1,233 shares during the period. Ameritas Investment Partners Inc. grew its stake in shares of Bicara Therapeutics by 73.0% in the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company's stock valued at $32,000 after acquiring an additional 1,474 shares in the last quarter. Tower Research Capital LLC TRC increased its position in Bicara Therapeutics by 419.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company's stock worth $44,000 after acquiring an additional 3,866 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Bicara Therapeutics in the 4th quarter worth about $45,000. Finally, Larson Financial Group LLC raised its stake in Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company's stock worth $62,000 after purchasing an additional 3,595 shares in the last quarter.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近增加或减少了对 BCAX 的持股。Legal &amp; General Group Plc 在第二季度将其在 Bicara Therapeutics 的持股增加了 64.1%。Legal &amp; General Group Plc 目前拥有 3,156 股公司股票，价值 29,000 美元，此前在该期间内又购买了 1,233 股。Ameritas Investment Partners Inc.在第二季度将其在 Bicara Therapeutics 的持股增加了 73.0%。Ameritas Investment Partners Inc.目前拥有 3,493 股公司股票，价值 32,000 美元，此前在上一季度又收购了 1,474 股。Tower Research Capital LLC TRC 在第二季度将其在 Bicara Therapeutics 的持股增加了 419.3%。Tower Research Capital LLC TRC 目前拥有 4,788 股公司股票，价值 44,000 美元，此前在该期间内又收购了 3,866 股。Mirae Asset Global Investments Co. Ltd.在第四季度收购了 Bicara Therapeutics 的新股份，价值约 45,000 美元。最后，Larson Financial Group LLC 在第三季度将其在 Bicara Therapeutics 的持股增加了 1,015.5%。Larson Financial Group LLC 目前拥有 3,949 股公司股票，价值 62,000 美元，此前在上一季度又购买了 3,595 股。</p>
</div><h2>About Bicara Therapeutics</h2>
<div class="lb-trans"><h2>关于 Bicara Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.</p>
<div class="lb-trans"><p>Bicara Therapeutics 是一家临床阶段的生物制药公司，致力于开发新型基于神经激素的疗法，以治疗精神和神经疾病。公司的研究专注于利用大脑中的内源性信号通路，旨在为现有药物无法充分解决的疾病提供新的治疗选择。Bicara 应用专有的肽工程和鼻用给药平台，以优化中枢神经系统的吸收和治疗效果。</p>
</div><p>The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.</p>
<div class="lb-trans"><p>公司的主要候选药物包括 PST-001，一种用于产后抑郁症的鼻用抗加压素 1A 受体拮抗剂，以及 PST-002，一种正在研究用于社交焦虑和自闭症谱系障碍的催产素受体调节剂。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Bicara Therapeutics</li>
<li>Your Signature Is Missing – Act Before It’s Too Late</li>
<li>What Expenses Can Be Deducted From Capital Gains Tax?</li>
<li>Punch these codes into your ordinary brokerage account</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>Buy This Stock at 9:30 AM on MONDAY!</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票比 Bicara Therapeutics 更好</li>
<li>您的签名缺失 - 在为时已晚之前采取行动</li>
<li>什么费用可以从资本利得税中扣除？</li>
<li>将这些代码输入您的普通经纪账户</li>
<li>用这 4 个简单步骤 “防止美联储影响” 您的银行账户</li>
<li>在星期一上午 9:30 购买这只股票！</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkNBWA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=BCAX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bicara Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元于 Bicara Therapeutics 吗？</h2>
</div><p>Before you consider Bicara Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Bicara Therapeutics 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Bicara Therapeutics 并不在名单上。</p>
</div><p>While Bicara Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Bicara Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Bicara Therapeutics（NASDAQ:BCAX）的首席财务官出售了 1,882 股股票